Kitov Pharmaceuticals Holdings, Zock oder mehr?
03.06.18 17:34
#1
clint65
Kitov Pharmaceuticals Holdings, Zock oder mehr?
Das Kombipräparat Consensi (von zwei bereits am Markt befindlichen Produkten) wurde am Donnerstag, den 31.05.2018 von der FDA (mit Blackboxwarnung) zugelassen:
https://www.nasdaq.com/press-release/...d-hypertension-20180531-01030
Es gab unmittelbar danach eine Kapitalerhöhung am Freitag, den 01.06.2018, was den möglichen Anstieg ausgebremst haben sollte:
http://kitovpharma.investorroom.com/news-releases?item=63
Mit der Zulassung durch die FDA zahlt der chinesische Lizenzpartner Milestones:
http://kitovpharma.investorroom.com/news-releases?item=62
Der CEO Isaak ist in Amerika angeklagt, Verfahren offen...
Interessant ist die Personalie John Paul Waymack, ein ehemaliger FDA Medical Officer:
http://kitovpharma.com/about/profile/about-us/
Die augenblickliche Marktkapitalisierung liegt beim aktuellen Kurs von 2,58 Dollar unter 30 Millionen Dollar (nicht fully diluted!):
https://www.nasdaq.com/symbol/ktov
Kitov ist eine kleine "Biotechklitsche" aus Israel; jeder sollte sich des Risikos bewußt sein!!!
https://www.nasdaq.com/press-release/...d-hypertension-20180531-01030
Es gab unmittelbar danach eine Kapitalerhöhung am Freitag, den 01.06.2018, was den möglichen Anstieg ausgebremst haben sollte:
http://kitovpharma.investorroom.com/news-releases?item=63
Mit der Zulassung durch die FDA zahlt der chinesische Lizenzpartner Milestones:
http://kitovpharma.investorroom.com/news-releases?item=62
Der CEO Isaak ist in Amerika angeklagt, Verfahren offen...
Interessant ist die Personalie John Paul Waymack, ein ehemaliger FDA Medical Officer:
http://kitovpharma.com/about/profile/about-us/
Die augenblickliche Marktkapitalisierung liegt beim aktuellen Kurs von 2,58 Dollar unter 30 Millionen Dollar (nicht fully diluted!):
https://www.nasdaq.com/symbol/ktov
Kitov ist eine kleine "Biotechklitsche" aus Israel; jeder sollte sich des Risikos bewußt sein!!!
102 Postings ausgeblendet.
22.03.21 11:13
#107
dyesbis
es geht voran ...
es geht voran
https://www.globenewswire.com/news-release/2021/...anced-Cancers.html
https://www.globenewswire.com/news-release/2021/...anced-Cancers.html
13.04.21 19:51
#112
Blauschwert
Veröffentlichung
13.04.2021
TEL AVIV, Israel, April 13, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that additional preclinical data supporting the mechanism of action of NT219, a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3, were presented in a poster entitled "Adaptation of colorectal cancer cells to the brain microenvironment: The role of IRS2," at the American Association of Cancer Research (AACR) 2021 Annual Meeting. These data update and expand on the results previously reported by the Company from its collaboration with Professor Ido Wolf, Head of the Oncology Division at Tel Aviv Sourasky Medical Center.
Colorectal cancer (CRC) represents the fourth most frequent cause of brain metastasis, which is the most common brain tumor. The study included an analysis of more than 16,000 human CRC local and metastasis samples, and revealed increased amplification of IRS2 in brain metastases.
In an in vitro system mimicking the brain microenvironment, IRS2-overexpressed CRC cells showed prolonged survival. Importantly, transcriptomic analysis demonstrated significant enrichment of the oxidative phosphorylation (OXPHOS) pathway by IRS2. CRC cells expressing IRS2 showed increased mitochondrial activity and glycolysis-independent viability. Inhibition of IRS2 using NT219 dose-dependently inhibited IRS2-expressing cells viability and OXPHOS genes expression.
The Wnt/β-catenin pathway was among the most significantly enriched pathways in the brain metastasis, as IRS2-expressing cells showed increased transcriptional activity of the β-catenin. In addition, NT219 decreased the transcriptional activity of β-catenin in IRS2-expressing CRC cells to a greater extent than AKT and PI3K inhibitors, and most significantly suggested relevance of IRS2 in activating β-catenin. It was further shown that 5-FU, a chemotherapy approved for treating CRC, elevated β-catenin expression, and that NT219 diminished both 5FU-induced and the basal level of the β-catenin expression. Utilizing an intracranial animal model, it was also demonstrated that while 5-FU alone had no significant effect, the combination of 5-FU and NT219 significantly inhibited the formation of brain metastasis and extended survival rates of the study mice.
"We are excited about these highly encouraging study results," said Bertrand Liang, M.D., Ph.D., Chief Medical Officer of Purple Biotech. "These compelling data provide important insights regarding the role of IRS2 in promoting CRC brain metastasis, and suggest that novel agents such as NT219 have the potential to effectively inhibit the development of brain metastasis. Our ongoing Phase 1/2 clinical trial of NT219 as monotherapy for the treatment of solid tumors, followed by a dose escalation of NT219 in combination with cetuximab, an epithelial growth factor receptor (EGFR) blocking monoclonal antibody, for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer, is proceeding with enrollment as planned and we continue to expect the availability of top-line data from the first part of this study in the second half of this year."
The poster presentation is available at https://purple-biotech.com/2021/04/12/...irtual-meeting-poster-2021/.
TEL AVIV, Israel, April 13, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that additional preclinical data supporting the mechanism of action of NT219, a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3, were presented in a poster entitled "Adaptation of colorectal cancer cells to the brain microenvironment: The role of IRS2," at the American Association of Cancer Research (AACR) 2021 Annual Meeting. These data update and expand on the results previously reported by the Company from its collaboration with Professor Ido Wolf, Head of the Oncology Division at Tel Aviv Sourasky Medical Center.
Colorectal cancer (CRC) represents the fourth most frequent cause of brain metastasis, which is the most common brain tumor. The study included an analysis of more than 16,000 human CRC local and metastasis samples, and revealed increased amplification of IRS2 in brain metastases.
In an in vitro system mimicking the brain microenvironment, IRS2-overexpressed CRC cells showed prolonged survival. Importantly, transcriptomic analysis demonstrated significant enrichment of the oxidative phosphorylation (OXPHOS) pathway by IRS2. CRC cells expressing IRS2 showed increased mitochondrial activity and glycolysis-independent viability. Inhibition of IRS2 using NT219 dose-dependently inhibited IRS2-expressing cells viability and OXPHOS genes expression.
The Wnt/β-catenin pathway was among the most significantly enriched pathways in the brain metastasis, as IRS2-expressing cells showed increased transcriptional activity of the β-catenin. In addition, NT219 decreased the transcriptional activity of β-catenin in IRS2-expressing CRC cells to a greater extent than AKT and PI3K inhibitors, and most significantly suggested relevance of IRS2 in activating β-catenin. It was further shown that 5-FU, a chemotherapy approved for treating CRC, elevated β-catenin expression, and that NT219 diminished both 5FU-induced and the basal level of the β-catenin expression. Utilizing an intracranial animal model, it was also demonstrated that while 5-FU alone had no significant effect, the combination of 5-FU and NT219 significantly inhibited the formation of brain metastasis and extended survival rates of the study mice.
"We are excited about these highly encouraging study results," said Bertrand Liang, M.D., Ph.D., Chief Medical Officer of Purple Biotech. "These compelling data provide important insights regarding the role of IRS2 in promoting CRC brain metastasis, and suggest that novel agents such as NT219 have the potential to effectively inhibit the development of brain metastasis. Our ongoing Phase 1/2 clinical trial of NT219 as monotherapy for the treatment of solid tumors, followed by a dose escalation of NT219 in combination with cetuximab, an epithelial growth factor receptor (EGFR) blocking monoclonal antibody, for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer, is proceeding with enrollment as planned and we continue to expect the availability of top-line data from the first part of this study in the second half of this year."
The poster presentation is available at https://purple-biotech.com/2021/04/12/...irtual-meeting-poster-2021/.
26.04.21 08:29
#114
dyesbis
und wieder ein kleines Update
https://www.globenewswire.com/news-release/2021/...ncer-Patients.html
20.05.21 13:06
#115
Blauschwert
neue Veröffentlichung
https://www.pressviewer.com/...amp;p=2195304&I=1270120-b3h8I2r8t4
28.05.21 11:15
#117
Blauschwert
Präsentation announced
Purple Biotech to Present at the Jefferies Virtual Healthcare Conference
REHOVOT, Israel, May 26, 2021 -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 8:30am EST. The conference will take place from June 1 - June 4, 2021. Management will be available for one-on-one meetings.
Jefferies Virtual Healthcare Conference - June 1-4, 2021
Date: Friday, June 4, 2021
Time: 8:30-8:55am EST
REHOVOT, Israel, May 26, 2021 -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 8:30am EST. The conference will take place from June 1 - June 4, 2021. Management will be available for one-on-one meetings.
Jefferies Virtual Healthcare Conference - June 1-4, 2021
Date: Friday, June 4, 2021
Time: 8:30-8:55am EST
28.05.21 14:05
#118
dyesbis
spannenderweise ...
spannenderweise beides an einem Tag
zuerst die Jefferies Virtual Healthcare Conference und später am gleichen Tag werden die ersten Daten von NT219 aus Tests an Menschen präsentiert
die FOMO ist auch schon recht stark
heute hab ich schon 5,50 Dollar premarket gesehen
zuerst die Jefferies Virtual Healthcare Conference und später am gleichen Tag werden die ersten Daten von NT219 aus Tests an Menschen präsentiert
die FOMO ist auch schon recht stark
heute hab ich schon 5,50 Dollar premarket gesehen
04.06.21 12:35
#121
Kicky
Rankings Purple Biotech ADR
https://stocktwits.com/rankings PPBT steigt heute 12,6 % bei Tradegate
04.06.21 15:43
#122
Kicky
Purple Biotech new clinical data from NT2 at Asco
https://seekingalpha.com/news/...ta-from-nt219-at-asco-annual-meeting
07.06.21 11:13
#125
Vassago
PPBT 5.10$ (vorbörslich -14%)
Freitag -12%, heute vorbörslich nochmal -14%. Das kann eigentlich nur mit den NT219 Daten zusammenhängen die auf der ASCO veröffentlicht werden/wurden.
https://seekingalpha.com/news/...ta-from-nt219-at-asco-annual-meeting
https://seekingalpha.com/news/...ta-from-nt219-at-asco-annual-meeting